Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease ...

Woodside Energy has held talks with several potential buyers of stakes in its Louisiana liquefied natural gas plant, ...

Background Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports on Wall Street.

Johnson & Johnson entrusted its deal to just three lead managers: Citigroup, Deutsche Bank and Goldman Sachs. It did not ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Daniel Ghinn explores the processes behind launching LillyPad, global pharmaceutical company Eli Lilly’s corporate ... Industry conference in London. There were enough other companies already ...

Schulich Medicine & Dentistry research operations lead Kristy Coleman and professor Dr. Elizabeth Finger (L to R) found intermittent dosing of oxytocin can help improve apathy symptoms in ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

Global stocks mostly rose Thursday on easing trade tensions, with London and Frankfurt hitting record highs ahead of key US ...